IGF-I and IGFBP-1 in Relation to Body Composition and Physical Performance in Female Olympic Athletes.
Adult
Athletes
/ statistics & numerical data
Athletic Performance
/ physiology
Biomarkers
/ blood
Body Composition
Bone Density
Case-Control Studies
Cross-Sectional Studies
Exercise
Female
Follow-Up Studies
Humans
Insulin-Like Growth Factor Binding Protein 1
/ blood
Insulin-Like Growth Factor I
/ analysis
Physical Functional Performance
Prognosis
GFBP-1 - insulin-like growth factor binding protein 1
IGF-I - insulinlike growth factor 1
athletic performance
body composition
female athlete
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
05
2021
accepted:
31
07
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
11
2
2022
Statut:
epublish
Résumé
Insulin- like growth factor-I (IGF-I) is an anabolic hormone that may affect athletic performance in female athletes, and insulin-like growth factor binding protein-1 (IGFBP-1) is an important regulator of bioactive IGF-I. There is limited knowledge of the role of endogenous IGF-I and IGFBP-1 for body composition and physical performance in female elite athletes. To examine IGF-I, age adjusted IGF-I (IGFSD), IGFBP-1 and insulin in female Olympic athletes compared with controls and different sport categories, and in relation to body composition and physical performance in the athletes. Female athletes (n=103) and untrained controls (n=113) were included in this cross-sectional study. Body composition was established by dual-energy X-ray absorptiometry. Serum IGF-I and IGFBP-1 were analyzed by radioimmunoassay and IGFSD was calculated. Insulin was analyzed by electrochemiluminescence immunoassay. Athletes were offered to participate in standardized physical fitness tests. The athletes demonstrated significantly higher IGF-I, IGFSD and IGFBP-1 and lower insulin levels than controls (p<0.05, p<0.05, p<0.01, p<0.001 respectively). Power athletes had significantly higher IGFSD compared to both endurance and technical athletes (p<0.05, p<0.01, respectively). In athletes and controls combined, significant positive correlations were found between IGF variables and higher bone mineral density (BMD) and lean mass and lower fat percent. IGF-I was positively correlated with squat jump (r We found higher IGF-I, IGFSD and IGFBP-1 in female athletes than controls, and the highest IGFSD in power athletes. IGF-I and IGFBP-1 were related to increased BMD and lean mass and lower fat percent, as well as were positively associated with physical fitness tests. Future studies are needed to elucidate if these results reflect adaptive responses to physical activity or genetic predisposition.
Identifiants
pubmed: 34484121
doi: 10.3389/fendo.2021.708421
pmc: PMC8415455
doi:
Substances chimiques
Biomarkers
0
IGF1 protein, human
0
IGFBP1 protein, human
0
Insulin-Like Growth Factor Binding Protein 1
0
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
708421Informations de copyright
Copyright © 2021 Eklund, Hellberg, Berglund, Brismar and Hirschberg.
Déclaration de conflit d'intérêts
BB is the medical director for the Swedish Olympic Committee (SOC) and ALH is medical adviser to the SOC, the International Association of Athletic Federation (IAAF) and the International Olympic Committee (IOC). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Strength Cond Res. 2008 Nov;22(6):1779-84
pubmed: 18824929
Br J Sports Med. 2017 Sep;51(17):1301-1308
pubmed: 28646101
Med Sci Sports Exerc. 2010 Jan;42(1):39-49
pubmed: 20010131
Med Sci Sports Exerc. 2013 Mar;45(3):420-8
pubmed: 23034644
Ann Intern Med. 2010 May 4;152(9):568-77
pubmed: 20439575
J Clin Endocrinol Metab. 1996 Nov;81(11):3986-92
pubmed: 8923848
J Clin Endocrinol Metab. 2004 Sep;89(9):4364-70
pubmed: 15328063
J Mol Endocrinol. 2013 Dec 19;52(1):R107-23
pubmed: 24163428
Front Endocrinol (Lausanne). 2020 May 12;11:292
pubmed: 32528408
J Clin Endocrinol Metab. 1996 Mar;81(3):1224-31
pubmed: 8772603
Endocr Rev. 2019 Aug 1;40(4):1163-1185
pubmed: 31180479
J Clin Endocrinol Metab. 1995 Sep;80(9):2646-52
pubmed: 7545695
J Clin Endocrinol Metab. 2005 Feb;90(2):641-9
pubmed: 15546908
J Endocrinol Invest. 2008 Feb;31(2):138-45
pubmed: 18362505
Clin J Sport Med. 2013 May;23(3):197-201
pubmed: 23275346
Growth Horm IGF Res. 2010 Dec;20(6):404-10
pubmed: 20889360
J Appl Physiol (1985). 2015 Dec 1;119(11):1297-302
pubmed: 26429867
J Mol Endocrinol. 2018 Jul;61(1):T115-T137
pubmed: 29626053
Growth Horm IGF Res. 2009 Dec;19(6):491-6
pubmed: 19467892
Exp Mol Med. 2004 Feb 29;36(1):1-12
pubmed: 15031665
Mol Cell Endocrinol. 2018 Mar 15;464:65-74
pubmed: 28606865
Med Sci Sports Exerc. 2000 Nov;32(11):1902-7
pubmed: 11079520
Acta Endocrinol (Copenh). 1991 Jun;124(6):620-9
pubmed: 2068892
Growth Horm IGF Res. 2017 Jun;34:38-44
pubmed: 28514721
Endocr Rev. 1994 Feb;15(1):80-101
pubmed: 8156941
Maturitas. 1998 Jan 12;28(3):259-65
pubmed: 9571602
Hum Reprod. 1997 Oct;12(10):2123-8
pubmed: 9402266
J Clin Endocrinol Metab. 1999 Jun;84(6):2013-9
pubmed: 10372703
Sports Med. 2014 May;44(5):603-23
pubmed: 24497158
Growth Horm IGF Res. 2017 Feb;32:2-13
pubmed: 27693042
Growth Horm IGF Res. 2004 Oct;14(5):337-75
pubmed: 15336229
J Clin Endocrinol Metab. 1996 May;81(5):1791-7
pubmed: 8626837
Mol Metab. 2019 Jan;19:86-96
pubmed: 30392760
J Clin Endocrinol Metab. 2003 Jan;88(1):394-401
pubmed: 12519882
Trends Endocrinol Metab. 2011 May;22(5):171-8
pubmed: 21420315
Hum Reprod. 2010 Jan;25(1):85-93
pubmed: 19840988
Ann Intern Med. 2008 May 20;148(10):747-58
pubmed: 18347346
J Clin Endocrinol Metab. 2006 Nov;91(11):4424-32
pubmed: 16912136
Anal Bioanal Chem. 2013 Dec;405(30):9669-83
pubmed: 23934394
Acta Endocrinol (Copenh). 1984 Dec;107(4):563-70
pubmed: 6083690
Med Sci Sports Exerc. 2009 Jun;41(6):1241-8
pubmed: 19461542
J Appl Physiol (1985). 2010 Jul;109(1):112-20
pubmed: 20395543
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10188-93
pubmed: 9707622
Health Sci Rep. 2018 Mar 09;1(4):e32
pubmed: 30623067
J Clin Endocrinol Metab. 2015 Aug;100(8):3126-31
pubmed: 26046967
Br J Pharmacol. 2008 Jun;154(3):557-68
pubmed: 18500379
Br J Sports Med. 2018 Jun;52(11):687-697
pubmed: 29773536
Clin Endocrinol (Oxf). 2002 Dec;57(6):793-803
pubmed: 12460330
Clin Endocrinol (Oxf). 2010 Apr;72(4):520-6
pubmed: 19650783
Med Sci Sports Exerc. 2010 Jan;42(1):58-66
pubmed: 20010129
Endocr Rev. 2007 Oct;28(6):603-24
pubmed: 17785429
Clin Endocrinol (Oxf). 2014 Aug;81(2):294-305
pubmed: 24593684